Franklin Resources Inc Immuno Gen, Inc. Transaction History

Franklin Resources Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$12.46 - $29.95 $1.45 Million - $3.49 Million	-116,628 Reduced 92.33%	9,695 $287,000
Q3 2023 Nov 13, 2023	BUY	$14.09 - $19.87 $1.02 Million - $1.44 Million	72,637 Added 135.3%	126,323 $2 Million
Q2 2023 Aug 11, 2023	BUY	$3.75 - $20.05 $201,322 - $1.08 Million	53,686 New	53,686 $1.01 Million
Q1 2019 May 14, 2019	SELL	$2.41 - $5.91 $216,569 - $531,090	-89,863 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$3.94 - $9.7 $354,060 - $871,671	89,863 New	89,863 $431,000
Q3 2018 Nov 13, 2018	SELL	$8.6 - $11.26 $14.9 Million - $19.6 Million	-1,737,000 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$9.52 - $12.15 $8.91 Million - $11.4 Million	-935,400 Reduced 35.0%	1,737,000 $16.9 Million
Q1 2018 May 10, 2018	SELL	$6.7 - $12.95 $2.24 Million - $4.33 Million	-334,200 Reduced 11.12%	2,672,400 $28.1 Million
Q4 2017 Feb 14, 2018	BUY	$5.07 - $7.92 $992,199 - $1.55 Million	195,700 Added 6.96%	3,006,600 $19.3 Million
Q3 2017 Nov 13, 2017	BUY	$5.4 - $8.47 $15.2 Million - $23.8 Million	2,810,900	2,810,900 $21.5 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

Stay updated on Franklin Resources Inc with notifications on news.